LFB XENOTHERA agreement to manufacture XAV-19 candidate therapy for coronavirus, including COVID-19, infections April 15, 2020 READ MORE > FDA approves SEVENFACT®, a new recombinant coagulation Factor VIIa [coagulation factor VIIa (recombinant)-jncw] April 6, 2020 READ MORE > Development of potential COVID-19 hyperimmune therapy April 6, 2020 READ MORE > LFB Future Strategy February 19, 2019 READ MORE > The LFB Group A leader in the field of biopharmaceuticals in Europe The LFB Group Cultivating life-changing therapeutic proteins The LFB Group In the news
